Yogic Breathing and IBS

IBS - Irritable Bowel Syndrome Clinical Trial

Official title:

Effects of Yogic Breathing on Microvascular Endothelial Function and Symptoms in Participants With IBS

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04225104
• Other study ID #: 6275
• Status: Completed
• Phase: N/A
• Start date: April 15, 2019
• Est. completion date: March 1, 2020

Study information

• Verified date: March 2021
• Source: Texas State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Adults with irritable bowel syndrome (IBS) are being randomized to a yogic breathing or control condition. Participants randomized to the yogic breathing group will be asked to complete a 2-minute yogic breathing video 5 to 7 days per week at home for 4 weeks and control group participants will be asked to maintain their current activities. Participants in this group will be given access to the yogic breathing video at the end of the 4-week control period. IBS symptoms and autonomic and vascular function will be assessed at baseline and at the end of week 4 in both groups.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: March 1, 2020
• Est. primary completion date: February 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Must have a formal diagnosis of IBS and not be enrolled in any other clinical trials.

Exclusion Criteria:

• 1) current, regular practice of yogic breathing at least 5 minutes per day and 2) chronic obstructive pulmonary disease

Related Conditions & MeSH terms

• IBS - Irritable Bowel Syndrome
• Irritable Bowel Syndrome

Intervention

Behavioral:
• Yogic breathing intervention
Yogic breathing will be completed while following a video provided by the investigative team. Breathing practices consist of slow, deep, relaxation breathing and are led by a certified yoga instructor.

Locations

Country	Name	City	State
United States	Stacy Hunter	San Marcos	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Texas State University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	IBS Symptoms	IBS-Symptom Severity Scale will be administered.	Once at baseline
Primary	IBS Symptoms	IBS-Symptom Severity Scale will be administered.	Once at the end of week 2
Primary	IBS Symptoms	IBS-Symptom Severity Scale will be administered.	Once at the end of week 4
Primary	Autonomic function	Heart rate variability will be assessed.	Once at baseline
Primary	Autonomic function	Heart rate variability will be assessed.	Once at the end of week 2
Primary	Autonomic function	Heart rate variability will be assessed.	Once at the end of week 4
Primary	Autonomic function	Exercise heart rate recovery will be measured.	Once at baseline
Primary	Autonomic function	Exercise heart rate recovery will be measured.	Once at the end of week 2
Primary	Autonomic function	Exercise heart rate recovery will be measured.	Once at the end of week 4
Primary	Microvascular function	Laser Doppler flowmetry at baseline and in response to local heating will be measured.	Once at baseline
Primary	Microvascular function	Laser Doppler flowmetry and in response to local heating will be measured.	Once at the end of week 4